References
- Mejía-Rodríguez O, Alvarez-Aguilar C, Vega-Gómez EH, Belio-Caro F, Vargas-Espinosa MJ, Paniagua-Sierra RJ. Bromocriptine induces regression of left ventricular hypertrophy in peritoneal dialysis patients. Proc West Pharmacol Soc. 2005;48:122–125
- Li H, Wang S. Organic nitrates favor regression of left ventricular hypertrophy in hypertensive patients on chronic peritoneal dialysis. Int J Mol Sci. 2013;14:1069–1079
- Quaschning T, Kocak S, Bauer C, Neumayer HH, Galle J, Hocher B. Increase in nitric oxide bioavailability improves endothelial function in endothelin-1 transgenic mice. Nephrol Dial Transplant. 2003;18:479–483
- Dhaun N, Goddard J, Webb JD. The endothelin system and its antagonism in chronic kidney disease. JASN. 2006;17(4):943–955
- Agapitov VA, Haynes GW. Role of endothelin in cardiovascular disease. Rev Bras Hipertens. 2003;10:87–105
- Rabelink TJ, de Boer HC, van Zonneveld J. Endothelial activation and circulating markers of endotelial activation in kidney disease. Nat Rev Nephrol. 2010;6(6):404–414
- Löwbeer C, Ottosson-Seeberger A, Gustafsson AS, Norrman R, Hulting J, Gutierrez A. Increased cardiac troponin T and endothelin-1 concentrations in dialysis patients may indicate heart disease. Nephrol Dial Transplant. 1999;14(8):1948–1955
- Jacobi J, Tsao SP. Asymmetrical dimethylarginine in renal disease: limits of variation or variation limits? Am J Nephrol. 2008;28(2):224–237
- Baylis C. Nitric oxide deficiency in chronic kidney disease. AJP-Renal Physiol. 2008;294(1):F1–F9
- Devereux R, Alonso D, Lutas E, Gottlieb G, Compo E, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450–458
- Liu H, Peng Y, Liu F, et al. Correlation between endothelin-1 and atherosclerosis in chronic hemodialysis patinets. J Nephrol. 2010;23(5):593–602
- Ochodnicky P, Vettoretti S, Henning RH, Buikema H, Van Dokkum RP, de Zeeuw D. Endothelial dysfunction in chronic kidney disease: determinant of susceptibility to end-organ damage and therapeutic response. J Nephrol. 2006;19(3):246–258
- de Bie KM, Ajmone Marsan N, Gaasbeek A, et al. Left ventricular diastolic dysfunction in dialysis patients assessed by novel speckle tracking strain rate analysis: prevalence and determinants. Int J Nephrol. 2012;2012:963504
- Zoccali C, Benedetto FA, Mallamaci F, et al. Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression. Kidney Int. 2004;65(4):1492–1498
- London GM. Left ventricular alterations and end-stage renal disease. Nephrol Dial Transplant. 2002;17(1):29–36
- Glassock RJ, Pecoits-Filho R, Barberato SH. Left ventricular mass in chronic kidney disease and ESRD. Clin J Am Soc Nephrol. 2009;4(1):S79–S91
- Vanholder R, De Smet R, Glorieux G, et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 2003;63(5):1934–1943
- Demuth K, Blacher J, Guerin AP, et al. Endothelin and cardiovascular remodelling in end stage renal disease. Nephrol Dial Transplant. 1998;13:375–383
- Zoccali C, Mallamaci F, Maas R, et al. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int. 2002;62:339–345